Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
Titel:
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
Auteur:
Pollack, M.H. Betof, A. Dearden, H. Rapazzo, K. Valentine, I. Brohl, A.S. Ancell, K.K. Long, G.V. Menzies, A.M. Eroglu, Z. Johnson, D.B. Shoushtari, A.N.